基孔肯雅疫苗价值概况
基孔肯雅病毒(CHIKV)是一种蚊媒甲病毒,所致基孔肯雅病死亡率低但急性和慢性发病率高,疾病负担重。约40%感染者会发展为慢性关节炎,可能持续数月或数年。目前尚无获批的抗病毒药物或疫苗,疫苗的公共卫生价值在于减少疾病负担和经济损失,并预防或减少慢性疾病。该疫苗价值概况由多学科专家组基于现有公开信息制定,旨在评估在研疫苗的潜在公共卫生、经济和社会价值。
要点
- 约40%的基孔肯雅病毒感染者会发展为慢性关节炎,可能持续数月或数年。
- 目前尚无获批的基孔肯雅抗病毒药物或疫苗。
- 疫苗的公共卫生价值在于减少疾病负担和经济损失,并预防或减少慢性疾病。
核心结论
- 基孔肯雅疫苗的潜在公共卫生价值在于减少疾病负担和经济损失,并预防或减少慢性疾病,尤其在低收入和中等收入国家及社会经济贫困地区。
研究设计与样本
- 该疫苗价值概况由来自学术界、非营利组织、公私合作伙伴关系和多边组织的主题专家工作组制定;仅使用现有和公开可用的信息。
主要发现
- 基孔肯雅病死亡率低但急性和慢性发病率高,导致总体疾病负担高。
- 约40%的基孔肯雅病毒感染者会发展为慢性关节炎,可能持续数月或数年。
- 慢性疾病包括持续性关节痛,可导致疲劳和疼痛,严重到限制正常活动。
- 目前尚无获批的基孔肯雅抗病毒药物或疫苗。
- 低收入和中等收入国家及社会经济贫困地区更可能发生更多感染和更严重结局。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chikungunya virus (CHIKV) a mosquito-borne alphavirus is the causative agent of Chikungunya (CHIK), a disease with low mortality but high acute and chronic morbidity resulting in a high overall burden of disease. After the acute disease phase, chronic disease including persistent arthralgia is very common, and can cause fatigue and pain that is severe enough to limit normal activities. On average, around 40% of people infected with CHIKV will develop chronic arthritis, which may last for months or years. Recommendations for protection from CHIKV focus on infection control through preventing mosquito proliferation. There is currently no licensed antiviral drug or vaccine against CHIKV. Therefore, one of the most important public health impacts of vaccination would be to decrease burden of disease and economic losses in areas impacted by the virus, and prevent or reduce chronic morbidity associated with CHIK. This benefit would particularly be seen in Low and Middle Income Countries (LMIC) and socio-economically deprived areas, as they are more likely to have more infections and more severe outcomes. This 'Vaccine Value Profile' (VVP) for CHIK is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic and societal value of vaccines in the development pipeline and vaccine-like products.This VVP was developed by a working group of subject matter experts from academia, non-profit organizations, public private partnerships, and multi-lateral organizations. All contributors have extensive expertise on various elements of the CHIK VVP and collectively aimed to identify current research and knowledge gaps.The VVP was developed using only existing and publicly available information.
引用
- Flandes X, Hansen CA, Palani S, et al. Vaccine value profile for Chikungunya. Vaccine. 2023. PMID: 38407992. doi:10.1016/j.vaccine.2023.07.069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。